Elevated hsa-miR-99a levels in maternal plasma may indicate congenital heart defects.

@article{Kehler2015ElevatedHL,
  title={Elevated hsa-miR-99a levels in maternal plasma may indicate congenital heart defects.},
  author={Lars Kehler and Orsolya B{\'i}r{\'o} and Levente L{\'a}z{\'a}r and J{\'a}nos Rig{\'o} and B{\'a}lint Nagy},
  journal={Biomedical reports},
  year={2015},
  volume={3 6},
  pages={
          869-873
        }
}
The current standard for prenatal screening is mostly based on biochemical marker tests and the use of ultrasonography. There is no secure stand-alone screening marker for congenital heart defects (CHDs). MicroRNAs (miRNAs) that are associated with cardiogenesis enter the maternal peripheral bloodstream during pregnancy and allow non-invasive prenatal testing (NIPT). The present study investigated the plasma expression profile of fetal hsa-miR-99a in maternal blood. Peripheral blood samples… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Let - 7 c as potential maternal serum miRNA biomarker in fetal congenital heart defects

L Lazar, O Biro, J Rigo, B Nagy
  • Biomed Rep
  • 2014

The global burden of congenital heart disease

JI Hoffman
  • Cardiovasc J Afr
  • 2013

microRNAs in cardiovascular development.

  • Journal of molecular and cellular cardiology
  • 2012

The meaning of cost for families of children with congenital heart disease.

  • Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2010